Compare SGRY & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGRY | SRPT |
|---|---|---|
| Founded | 2004 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 2.4B |
| IPO Year | 2015 | 2000 |
| Metric | SGRY | SRPT |
|---|---|---|
| Price | $12.39 | $17.15 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 28 |
| Target Price | $22.25 | ★ $25.76 |
| AVG Volume (30 Days) | 1.8M | ★ 2.0M |
| Earning Date | 03-02-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.14 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,145,438,000.00 | ★ $2,198,237,000.00 |
| Revenue This Year | $9.71 | N/A |
| Revenue Next Year | $7.82 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $12.12 | $10.42 |
| 52 Week High | $24.60 | $80.26 |
| Indicator | SGRY | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 33.43 | 45.46 |
| Support Level | $12.25 | $17.05 |
| Resistance Level | $16.15 | $19.55 |
| Average True Range (ATR) | 0.73 | 0.83 |
| MACD | -0.18 | 0.13 |
| Stochastic Oscillator | 7.01 | 63.11 |
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.